Compare CRMT & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRMT | KTTA |
|---|---|---|
| Founded | 1981 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 18.1M |
| IPO Year | 2026 | 2021 |
| Metric | CRMT | KTTA |
|---|---|---|
| Price | $3.05 | $0.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $29.50 | $3.00 |
| AVG Volume (30 Days) | 231.1K | ★ 290.8K |
| Earning Date | 06-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.07 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,281,502,000.00 | $486,559.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3130.37 |
| 52 Week Low | $1.38 | $0.28 |
| 52 Week High | $47.93 | $2.06 |
| Indicator | CRMT | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 53.85 |
| Support Level | $1.38 | $0.48 |
| Resistance Level | $3.67 | $0.52 |
| Average True Range (ATR) | 0.28 | 0.04 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 14.25 | 71.95 |
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.